InterMune said to be working with Evercore on strategic options
It sounds like this InterMune situation is heating up.
Good sources tell me InterMune - a US-based bio-pharmaceutical company that specialises in making a drug to treat idiopathic pulmonary fibrosis - has begun working with bankers from Evercore alongside long-standing financial adviser Goldman Sachs to look at 'strategic options' for the business.
It is believed the appointment of Evercore may lead to a formal auction of InterMune.
To be clear, though, it still early days in the dealmaking process and a transaction is by no means a certainty...
Register for free to see rest of this article and all public articles from BetavilleLogin / Register